Therapy News and Research

RSS

Wellmont partners with HealthSouth to open a new inpatient rehabilitation hospital in Bristol

Wellmont Health System and HealthSouth Corporation (NYSE: HLS) today announced that a joint venture entity formed by the two parties has been awarded a certificate of public need (COPN) to open a new inpatient rehabilitation hospital in Bristol, Va. The 25-bed hospital will enable more patients in Bristol and throughout Southwest Virginia to have access to comprehensive, high-quality rehabilitative services.

9 Sep 2009

Individuals with upper-GI symptoms visit general practitioners often

Patients with upper gastrointestinal (GI) complaints visit their general practitioner (GP) more often than patients with other conditions. Researchers writing in the open access journal BMC Family Practice found that people with dyspepsia, heartburn, epigastric discomfort and other upper-abdominal complaints had almost twice as many GP contacts, which were ultimately associated with problems in all organ systems.

9 Sep 2009

New procedure used for breast cancer surgery

Breast cancer surgeons and radiation oncologists at St. Joseph Hospital in Orange performed a new procedure combining removal of a patient’s breast tumor with the power of electron beam radiation in the operating room.

8 Sep 2009

KRYSTEXXA development and treatment failure gout to be presented

Savient Pharmaceuticals, Inc. announced that five abstracts relating to KRYSTEXXA (pegloticase) development and treatment failure gout will be presented at the 2009 ACR/ARHP Annual Scientific Meeting taking place in Philadelphia from October 16-21, 2009.

8 Sep 2009

Preliminary results of Phase III Gvhd trials announced by Osiris Therapeutics

Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced preliminary results for two phase III trials evaluating Prochymal for the treatment of acute graft versus host disease (GvHD). GvHD, the most common complication of bone marrow transplantation, is a life-threatening disease for which there is currently no approved treatment. Prochymal showed significant improvements in response rates in difficult-to-treat liver and gastrointestinal GvHD, however neither trial reached its primary endpoint.

8 Sep 2009

Opexa Therapeutics' ongoing development program for Tovaxin to be presented

Opexa Therapeutics, Inc., a company developing Tovaxin, a personalized T-cell immunotherapy for multiple sclerosis (MS), today announced that Neil K. Warma, Opexa’s president and chief executive officer, will deliver a corporate presentation at Rodman & Renshaw’s 11th Annual Healthcare Conference.

8 Sep 2009

DOR's Phase 1/2 clinical trial for prevention of radiation enteritis receives NIH grant

DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biotechnology company, announced today that the National Institutes of Health (NIH) has awarded DOR a Small Business Innovation Research (SBIR) grant to support the conduct of a Phase 1/2 clinical trial evaluating DOR201, a time-release formulation of oral beclomethasone dipropionate (oral BDP), for the prevention of acute radiation enteritis.

8 Sep 2009

Elsevier to launch new Health Sciences eBooks

Elsevier, the world's leading publisher of scientific, technical, and medical information products and services, announced today that nearly 250 health sciences titles published and/or publishing in 2009 and 2010 will be launched in October. These new eBook collections cover clinical content in clinical medicine, veterinary medicine, and health professions, furthering Elsevier's commitment to making health sciences content available electronically through ScienceDirect, its online scientific research platform.

8 Sep 2009

Axel Ullrich receives the 2009 Dr. Paul Janssen Award for Biomedical Research

Johnson & Johnson today honored the career achievements of Axel Ullrich, Ph.D., with the 2009 Dr. Paul Janssen Award for Biomedical Research. Dr. Ullrich received this award for his scientific discoveries that led to innovative new drugs including Herceptin((R)) (trastuzumab)*, a personalized medicine therapy, which was the first to target a specific type of breast cancer.

8 Sep 2009

Brainwave opens a new facility in Birchwood

National charity Brainwave, which provides home based therapy programmes for children with cerebral palsy and other conditions such as development delay, is opening a third Centre in Birchwood, Warrington to cope with the increasing demand for its services.

8 Sep 2009

Contraceptive pill likely cause for 20 percent drop in ovarian cancer rates

Ovarian cancer rates have fallen by almost 20 per cent in a decade, according to Cancer Research UK today (Wednesday).

8 Sep 2009

Specific targeting of brain tumors with an optical/magnetic resonance imaging nanoprobe across the blood-brain barrier

Earlier this year, researchers at the University of Washington reported that they had developed a toxin-nanoparticle combination that inhibits brain cancer invasion when added to tumor cells growing in culture.

7 Sep 2009

Nanotags pinpoint multiple cancer markers in live animals

Using nanoparticles designed specifically to produce a bright Raman spectroscopic signal, a team of investigators at the Center for Cancer Nanotechnology Excellence Focused on Therapy Response (Stanford University Center for Cancer Nanotechnology Excellence [CCNE]) has shown that it can simultaneously track as many as 10 different optical tags in a living animal.

7 Sep 2009

Nanotubes destroy kidney tumors

By injecting multiwalled carbon nanotubes (MWCNTs) into tumors and heating them with a quick, 30-second zap of a laser, a multi-institutional team of researchers from the Wake Forest University School of Medicine (WFUSOM), Wake Forest University Center for Nanotechnology and Molecular Materials, Rice University, and Virginia Polytechnic Institute and State University has developed a new type of therapy that effectively kills kidney tumors in nearly 80% of treated mice. Researchers say that the findings, which were published in the Proceedings of the National Academy of Sciences of the United States of America, suggest a potential future cancer treatment for humans.

7 Sep 2009

Nanoparticle-delivered suicide gene therapy effectively reduces ovarian tumor burden in mice

Nanoparticle delivery of diphtheria toxin-encoding DNA that expresses selectively in ovarian cancer cells reduced the burden of ovarian tumors in mice, and researchers expect that this therapy could be tested in humans with advanced ovarian cancer within 18 to 24 months, according to a report in Cancer Research. If additional tests are successful, these finding could lead to a new treatment for ovarian cancer, which now causes more than 15,000 deaths each year in the United States. Because it is usually diagnosed at a relatively late stage, ovarian cancer is one of the most deadly forms of the disease.

7 Sep 2009

Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth

When bees sting, they pump into their victims a peptide toxin called melittin that destroys cell membranes. Now, by encapsulating this extremely potent molecule within a nanoparticle, researchers at the Washington University School of Medicine in St. Louis have created a potential new type of anticancer therapy with the potential to target a wide range of tumors. This work was reported in the Journal of Clinical Investigation.

7 Sep 2009

Novo Nordisk initiates its share repurchase programme

On 7 August 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

From Novo Nordisk 7 Sep 2009

CIHR funds for Alzheimer's and stroke research

The Canadian Institutes of Health Research (CIHR) has announced a grant totaling more than a million dollars for John F. MacDonald's research on Alzheimer's disease.

7 Sep 2009

ASNM inaugral conference to discuss the latest in nanomedicine

Nanomedicine - the science and technology of diagnosing, treating and preventing disease to improve human health using nanotechnology - has the potential to revolutionize healthcare. Current and future products range from miniaturized "smart pills" that precision-target certain cancers to nanosensors that are capable of navigating through the body for early detection of disorders.

5 Sep 2009

European MAA for lubiprostone withdrawn by Sucampo Pharma Europe

Sucampo Pharma Europe, Ltd., a wholly-owned subsidiary of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP), today announced the withdrawal of its European marketing authorization application (MAA) for lubiprostone, 24 mcg, for the indication of Chronic Idiopathic Constipation (CIC).

5 Sep 2009